Clinical Trial

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-06.
Trial Details
NCT Number NCT06823427
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
Enrollment 60 participants
Start Date 2025-01-17
Primary Completion 2026-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-03-21